ArticleCancer cell international2026
Annexin A1 triggers autophagy to orchestrate radioiodine resistance in thyroid cancer via upregulating HMGB1.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study aims to investigate the mechanisms underlying ANXA1 and HMGB1-regulated autophagy in relation to growth and radioresistance in thyroid cancer cells. This exploration seeks to provide new theoretical insights and potential therapeutic targets for clinical management of 131I-resistant thyroid cancer.
methodsThe expression levels of ANXA1 in thyroid cancer tissues and cells were assessed through immunohistochemical staining and Western blot analysis. The correlation between ANXA1 expression levels and resistance to 131I was evaluated using cell viability assays (CCK-8), apoptosis analysis and colony formation assays. Additionally, the relationship between ANXA1 and autophagy was investigated by employing mRFP-GFP-LC3 virus transfection in conjunction with confocal microscopy to assess autophagic flux, as well as through Western blotting. Proteomics analysis, co-immunoprecipitation (Co-IP) results, along with various in vitro and in vivo experiments further elucidated the relationship between ANXA1 and HMGB1.
resultsThis study demonstrated for the first time that ANXA1 promotes the development of 131I resistance through the activation of autophagic flux. Proteomic analysis, co-immunoprecipitation (Co-IP) results, as well as various in vitro and in vivo experiments corroborated that ANXA1 activates autophagy by upregulating HMGB1 expression, thereby facilitating 131I drug resistance in thyroid cancer cells.
conclusionThis study unveils a novel mechanism by which ANXA1 fosters drug resistance to 131I in thyroid cancer via regulation of the HMGB1-mediated autophagy pathway. This not only provides a new theoretical framework for understanding iodine resistance in thyroid cancer but also identifies a potential molecular target for developing combination therapy strategies aimed at treating iodine-refractory thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.